The association of adiponectin and low-grade inflammation with the course of metabolic syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 3, 2012, Pages 285-291

  Ahonen, T M ^a   Saltevo, J T ^b   Kautiainen, H J ^b,c   Kumpusalo, E A ^d,e   Vanhala, M J ^b,d  

^a Palokka Health Centre   (Finland)

^b CENTRAL FINLAND CENTRAL HOSPITAL   (Finland)

^c ORTON   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; DISEASE COURSE; FEMALE; FINLAND; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PROGNOSIS; TIME;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; FINLAND; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; TIME FACTORS;

EID: 84857913188     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.07.001     Document Type: Article

References (30)

1. Eckel R.F., Grundy S.M., Zimmet P.Z. The metabolic syndrome. The Lancet 2005, 365(9486):1415-1428.
2. Ritchie S.A., Connell J.M.C. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases 2007, 17(4):319-326.
3. Tilg H., Moschen A. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology 2006, 6:772-783.
4. Chandran M., Phillips S.A., Ciaraldi T., Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450.
5. Hung J., McQuillan B.M., Thompson P.L., Beilby J.P. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. International Journal of Obesity 2008, 32:772-779.
6. Yeh E.T. High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clinical Cardiology 2005, 28(9):408-412.
7. Yap S.H., Moshage H.J., Hazenberg B.P., Roelofs H.M., Bijzet J., Limburg P.C., et al. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1991, 1091(3):405-408.
8. Castoldi G., Galimberti S., Riva C., Papagna R., Querci F., Casati M., et al. Association between serum values of C-reactive protein and cytokine production in whole blood of patients with type 2 diabetes. Clinical Science (London) 2007 Jul, 113(2):103-108.
9. Li J.T., Hou F.F., Guo Z.J., Shan Y.X., Zhang X., Liu Z.Q. Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scandinavian Journal of Immunology 2007 Nov, 66(5):555-562.
10. Juge-Aubry C.E., Somm E., Chicheportiche R., Burger D., Pernin A., Cuenod-Pittet B., et al. Regulatory effects of interleukin (IL)-1, interferon-β, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. Clinical Endocrinology and Metabolism 2004, 89(6):2652-2658.
11. Peeters A.C.T.M., Netea M.G., Janssen M.C.H., Kullberg B.J., Van der Meer J.W.M., Thien T. Pro-inflammatory cytokines in patients with essential hypertension. European Journal of Clinical Investigation 2001, 31(1):31-36.
12. Saltevo J., Vanhala M., Kautiainen H., Kumpusalo E., Laakso M. Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome. Mediators of Inflammation 2007, 93573.
13. Devaraj S., Torok N., Dasu M.R., Samols D., Jialal I. Adiponectin decreases C-reactive protein synthesis from endothelial cells. Evidence for an adipose tissue -vascular loop. Arteriosclerosis, Thrombosis, and Vascular Biology 2008, 28(7):1219-1221.
14. Grundy S.M., Hansen B., Smith S.C., Cleeman J.I., Kahn R.A. Report of the American heart association/national heart, lung, and blood institute/American diabetes association conference on scientific issues related to management. Circulation 2004, 109:551-556. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome.
15. Lloyd-Jones D.M., Liu K., Colangelo L.L., Yan L.J., Klein L., Loria C.M., et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the coronary artery risk development in young adults study. Circulation 2007, 115:1004-1011.
16. Carnethon M.R., Loria C.M., Hill J.O., Sidney S., Savage P.J., Liu K. Risk factors for the metabolic syndrome: the coronary artery risk development in young adults (CARDIA) study. Diabetes Care 2004, 27(11):2707-2715.
17. Steffen R., Potoczna N., Bieri N., Horber F.F. Successful multi-intervention treatment of severe obesity: a 7-year prospective study with 96% follow-up. Obesity Surgery 2009, 19(1):3-12.
18. Lundgren J.D., Malcolm R., Binks M., O'Neil P.M. Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss. International Journal Of Obesity(London) 2009, 33(1):144-150.
19. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. Journal of Allergy and Clinical Immunology 2008, 121(2):326-330.
20. Renaldi O., Pramono B., Sinorita H., Purnomo L.B., Asdie R.H., Asdie A.H. Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Medica Indonesiana 2009 Jan, 41(1):20-24.
21. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002 Jul 6, 360(9326):57-58.
22. Gonzalez-Gay M.A., Llorca J., Garcia-Unzueta M.T., Gonzalez-Juanatey C., De Matias J.M., Martin J., et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clinical and Experimental Rheumatology 2008, 26(4):596-603.
23. Salmenniemi U., Ruotsalainen E., Pihlajamäki J., Vauhkonen I., Kainulainen S., Punnonen K., et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004 Dec 21, 110(25):3842-3848.
24. Herder C., Brunner E.J., Rathman W., Strassburger K., Tabák A.G., Schloot N.C., et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes. The Whitehall II Study Diabetes Care 2009, 32:241-243.
25. Stenholm S., Koster A., Alley D.E., Visser M., Maggio M., Harris T.B., et al. Adipocytokines and the metabolic syndrome among older persons with and without obesity-the InCHIANTI study. Clin Endocrinol 2010, 73(1):55-65.
26. Dinarello C.A. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Annals of the NewYork Academy of Sciences 1998, 856:1-11.
27. Mandrup-Poulsen T. Beta cell apoptosis: stimuli and signaling. Diabetes 2001, 50(Suppl. 1):S58-S63.
28. Netea M.G., Hancu N., Blok W.L., Grigorescu-Sido P., Popa L., Popa V., et al. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine 1997 Apr, 9(4):284-287.
29. Richette P., François M., Vicaut E., Fitting C., Bardin T., Corvol M., et al. A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. Journal of Rheumatology 2008 Aug, 35(8):1650-1654.
30. Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target?. Canadian Journal of Cardiology 2010, 26(Suppl. A):41A-44A.